Hydroxychloroquine Trials Continue
Clinical trials
Derrick Haskins, communications director for the Department of Health, explained in an email to the Journal on Thursday that there are two trials for hydroxychloroquine: one is a registry trial for COVID-19 patients, and the other is a clinical trial for those exposed to COVID-19.
270 people were treated in the state’s registry trial for hydroxychloroquine last week, Haskins said. Those in the registry trial are hospitalized or outpatients who have tested positive for COVID-19 and receive hydroxychloroquine as treatment.
All of the 270 registry trial participants so far are Sanford patients in South Dakota and other states with Sanford hospitals. Haskins said the registry trial is open to individuals being treated by any health care provider in the state.
When asked about how the 270 patients in the trial were doing and whether any had recovered from COVID-19 yet, Malsam-Rysdon said to contact Sanford Health for any further hydroxychloroquine trial questions. At the time of publishing, Sanford has not yet responded to an email about the condition of the 270 patients in the trial.
Secondary to the registry trial is the state’s clinical trial, which does not yet have any participants.
Malsam-Rysdon said the clinical trial is going through the review process now and the department met with Sanford on Thursday to discuss the trial.
“We expect to have more information about it starting next week,” Malsam-Rysdon said.
The clinical trial would be for those exposed to COVID-19, including hospital workers, high-risk people, and those 60 and older.
The clinical trial will be randomized, so those who are exposed but not yet COVID-19 positive will either receive a placebo or hydroxychloroquine to see if the drug prevents them from contracting the coronavirus.
Haskins said the state has enough hydroxychloroquine to treat up to 100,000 people in either the registry or clinical arm of the study.
“The safety profile of the drug is continuing to be reviewed but with appropriate measures in place,” Malsam-Rysdon said, noting both the clinical and registry trials will likely go forward.
https://rapidcityjournal.com/news/local/state-and-regional/noem-to-speak-with-smithfield-workers-hydroxychloroquine-trial-continues/article_45df8093-f4d3-5500-9a27-2f21ad7c288f.html
Cabal fears this drug something fierce.
Keep eye out for what they use for 'placebo' in the prevention trial. We know they've already tried using Vitamin C as placebo in other 'studies'*, and Vitamin C is anything but a placebo.
*https://nypost.com/2020/04/05/ny-coronavirus-patients-being-treated-with-anti-malarial-drug/